MedTrace Logo

Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis

NCT01282528 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2011-01-25

No results posted yet for this study

Summary

To evaluate the predictive value of clinical, functional (HAQ), laboratory and US variables in relation to disease activity and radiographic outcome in patients with RA who start treatment with Remicade at 24 weeks.

Conditions

Interventions

BIOLOGICAL

infliximab

3mg/kg, at week 0, 2, 6, 14, 22

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Shenzhen People's Hospital

    collaborator OTHER

  • Changhai Hospital

    collaborator OTHER

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Yan Zhao, MD · Perking Union Medical College hospital

  • Xiaomei Leng, MD · Perking Union Medical College Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282528 on ClinicalTrials.gov